Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

Antiangiogenic therapy has become the most important treatment modality for patients with advanced hepatocellular carcinoma (HCC). In this study, the authors investigated levels of alpha‐fetoprotein (AFP) as a potential biomarker for treatment efficacy of antiangiogenic therapy.

[1]  Chih-Hung Hsu,et al.  Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. , 2010, Journal of Hepatology.

[2]  A. Cheng,et al.  Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.

[3]  Chiun Hsu,et al.  Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. , 2010, Contemporary clinical trials.

[4]  R. Finn,et al.  An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[6]  E. Raymond,et al.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. , 2009, The Lancet. Oncology.

[7]  C. Fuchs,et al.  Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. , 2009, The oncologist.

[8]  Marek Ancukiewicz,et al.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Gill,et al.  A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Mok,et al.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[12]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[13]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[14]  Masato Kato,et al.  Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. , 2008, Hepato-gastroenterology.

[15]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Chiun Hsu,et al.  Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study , 2008 .

[17]  G. Klintmalm,et al.  Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis , 2007, Alimentary pharmacology & therapeutics.

[18]  R. Kerbel,et al.  Molecular and cellular biomarkers for angiogenesis in clinical oncology. , 2007, Drug discovery today.

[19]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[20]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[21]  S. Juang,et al.  α‐fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma , 2005 .

[22]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[23]  J. Whang‐Peng,et al.  alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. , 2005, Alimentary pharmacology & therapeutics.

[24]  A. Lin,et al.  Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma , 2005, Cancer.

[25]  Y. Jeng,et al.  High α‐fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and β‐catenin mutations , 2004 .

[26]  S. Fan,et al.  Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma , 2004, The British journal of surgery.

[27]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[28]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[29]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[30]  Y. Jeng,et al.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. , 2004, International journal of cancer.

[31]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[32]  M. Makuuchi,et al.  α‐Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study , 2002 .

[33]  M. Makuuchi,et al.  alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. , 2002, Hepatology.

[34]  Barbara Mayer,et al.  Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  B. Seon,et al.  Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.

[36]  N. Nishida,et al.  Postoperative detection of α‐fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma , 2001 .

[37]  N. Nishida,et al.  Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. , 2001, Journal of gastroenterology and hepatology.

[38]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[41]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[42]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[43]  D. Ihde,et al.  Clinical trials in primary hepatocellular carcinoma: current status and future directions. , 1988, Cancer treatment reviews.